170 related articles for article (PubMed ID: 9688067)
21. Active self-healing encapsulation of vaccine antigens in PLGA microspheres.
Desai KG; Schwendeman SP
J Control Release; 2013 Jan; 165(1):62-74. PubMed ID: 23103983
[TBL] [Abstract][Full Text] [Related]
22. Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit.
Mohaghegh M; Tafaghodi M
Pharm Dev Technol; 2011 Feb; 16(1):36-43. PubMed ID: 20082579
[TBL] [Abstract][Full Text] [Related]
23. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues.
Crotts G; Park TG
J Microencapsul; 1998; 15(6):699-713. PubMed ID: 9818948
[TBL] [Abstract][Full Text] [Related]
24. Gamma irradiation of active self-healing PLGA microspheres for efficient aqueous encapsulation of vaccine antigens.
Desai KG; Kadous S; Schwendeman SP
Pharm Res; 2013 Jul; 30(7):1768-78. PubMed ID: 23515830
[TBL] [Abstract][Full Text] [Related]
25. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections.
Prior S; Gamazo C; Irache JM; Merkle HP; Gander B
Int J Pharm; 2000 Feb; 196(1):115-25. PubMed ID: 10675713
[TBL] [Abstract][Full Text] [Related]
26. Determination of protein loading in biodegradable polymer microspheres containing tetanus toxoid.
Gupta RK; Chang AC; Griffin P; Rivera R; Guo YY; Siber GR
Vaccine; 1997; 15(6-7):672-8. PubMed ID: 9178469
[TBL] [Abstract][Full Text] [Related]
27. Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF.
Pettit DK; Lawter JR; Huang WJ; Pankey SC; Nightlinger NS; Lynch DH; Schuh JA; Morrissey PJ; Gombotz WR
Pharm Res; 1997 Oct; 14(10):1422-30. PubMed ID: 9358556
[TBL] [Abstract][Full Text] [Related]
28. Stabilizing insulin-like growth factor-I in poly(D,L-lactide-co-glycolide) microspheres.
Meinel L; Illi OE; Zapf J; Malfanti M; Peter Merkle H; Gander B
J Control Release; 2001 Jan; 70(1-2):193-202. PubMed ID: 11166419
[TBL] [Abstract][Full Text] [Related]
29. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
[TBL] [Abstract][Full Text] [Related]
30. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
[TBL] [Abstract][Full Text] [Related]
31. Strategies for stabilising tetanus toxoid towards the development of a single-dose tetanus vaccine.
Schwendeman SP; Costantino HR; Gupta RK; Tobio M; Chang AC; Alonso MJ; Siber GR; Langer R
Dev Biol Stand; 1996; 87():293-306. PubMed ID: 8854030
[TBL] [Abstract][Full Text] [Related]
32. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid.
Gupta RK; Chang AC; Griffin P; Rivera R; Siber GR
Vaccine; 1996 Oct; 14(15):1412-6. PubMed ID: 8994315
[TBL] [Abstract][Full Text] [Related]
33. Preservation of lysozyme structure and function upon encapsulation and release from poly(lactic-co-glycolic) acid microspheres prepared by the water-in-oil-in-water method.
Pérez C; De Jesús P; Griebenow K
Int J Pharm; 2002 Nov; 248(1-2):193-206. PubMed ID: 12429473
[TBL] [Abstract][Full Text] [Related]
34. Induction of sustained and elevated immune responses to weakly immunogenic synthetic malarial peptides by encapsulation in biodegradable polymer microspheres.
Men Y; Gander B; Merkle HP; Corradin G
Vaccine; 1996 Oct; 14(15):1442-50. PubMed ID: 8994320
[TBL] [Abstract][Full Text] [Related]
35. Nucleic acid aptamers as stabilizers of proteins: the stability of tetanus toxoid.
Jain NK; Jetani HC; Roy I
Pharm Res; 2013 Jul; 30(7):1871-82. PubMed ID: 23568526
[TBL] [Abstract][Full Text] [Related]
36. The characterization of paclitaxel-loaded microspheres manufactured from blends of poly(lactic-co-glycolic acid) (PLGA) and low molecular weight diblock copolymers.
Jackson JK; Hung T; Letchford K; Burt HM
Int J Pharm; 2007 Sep; 342(1-2):6-17. PubMed ID: 17555895
[TBL] [Abstract][Full Text] [Related]
37. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
38. Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres.
Ibrahim MA; Ismail A; Fetouh MI; Göpferich A
J Control Release; 2005 Sep; 106(3):241-52. PubMed ID: 15970349
[TBL] [Abstract][Full Text] [Related]
39. Encapsulation-induced aggregation and loss in activity of gamma-chymotrypsin and their prevention.
Castellanos IJ; Cruz G; Crespo R; Griebenow K
J Control Release; 2002 Jun; 81(3):307-19. PubMed ID: 12044569
[TBL] [Abstract][Full Text] [Related]
40. A novel in vitro delivery system for assessing the biological integrity of protein upon release from PLGA microspheres.
Aubert-Pouëssel A; Bibby DC; Venier-Julienne MC; Hindré F; Benoît JP
Pharm Res; 2002 Jul; 19(7):1046-51. PubMed ID: 12180538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
